Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression

Contributed by: PR Newswire

Tags

Oncoinvent-AS-Reports

More Like This

Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients

Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases

Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update

Oncoinvent ASA: Invitation to Result Presentation Q4 2024

BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue

Oncoinvent ASA announces oversubscribed private placement

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Oncorena receives FDA approval to initiate studies in the US